The recalled products were either proven to contain or had the potential to contain N-nitrosodimethylamine, or NDMA, a human carcinogen, above the FDA-approved level.
Glenmark also ceased all distribution of its ranitidine products in the U.S. while it continues to test its products.
The recalled drugs were distributed nationwide to wholesalers, distributors and retailers.
Consumers with the recalled products should immediately discontinue use and consult with a physician about treatment options.
To date, Glenmark said it has not received any adverse event reports related to the recall.
Read the full article here.
More articles on pharmacy:
US sues CVS, accused of illegally dispensing drugs through Omnicare
Lawmakers expand definition of biologics in year-end spending bill
Purdue Pharma cuts ties with PhRMA
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.